Lantheus Medical Imaging Ansoff Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview – Access the Full Amsoff Matrix Analysis
This Lantheus Medical Imaging Amsoff Matrix Analysis helps you assess growth options across market penetration, market development, product development, and diversification. This page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Market Penetration
PYLARIFY Share Defense in Prostate Imaging
PYLARIFY remains the core PSMA PET driver for Lantheus Holdings, Inc., with FY2025 share defense centered on one product and one U.S. growth engine. Community-urology referral networks are the key battleground, because more clinicians are using PSMA PET for staging and recurrence, which lifts repeat scanning demand. The play is share gain, not just volume growth.
DEFINITY Retention Across Echo Accounts
DEFINITY helps Lantheus Holdings, Inc. hold a two-franchise base in cardiology imaging and oncology diagnostics, with DEFINITY acting as the second scaled product in hospital and outpatient care. In FY2025, this kind of installed use matters because echo labs are hard to displace once the workflow is set, so formulary access and simple protocols support account retention and renewal.
That stickiness can protect repeat use across echo accounts and keep switching costs high. It also supports cross-selling into a broader imaging portfolio, which helps defend share even when new entrants push for formulary space.
Access Support Converts Denials into Scans
Lantheus Holdings, Inc. uses access support and prior-auth help to turn a denied scan into a completed scan, which is a direct market-penetration lever.
In 2025, Lantheus reported full-year revenue of about $1.5 billion, with PYLARIFY still the main growth driver, showing how coverage friction matters to realized demand.
For imaging agents, payer rules decide whether latent demand becomes paid procedures, so reducing denials at imaging centers can lift scan volume without changing the product.
Field Effort Expands Ordering Across 3 Stakeholders
In FY2025, Lantheus Medical Imaging can widen penetration by pushing field teams across urology, oncology, and radiology, not just signing new sites. That matters most in prostate cancer, where a scan often needs aligned referral, ordering, and scheduling; more utilization per account lifts orders faster than site count alone. The U.S. prostate cancer market is large, with about 300,000 new cases a year.
Supply Reliability Protects a Short-Half-Life Franchise
Lantheus Holdings, Inc. protects market share by keeping supply steady for its short-half-life radiopharmaceutical franchise, where even one missed dose can push orders to rivals. In FY2025, that discipline matters more than ever as the installed base grows, because reliable production and distribution help defend recurring revenue and reduce disruption risk across hospital accounts.
Lantheus Deepens PYLARIFY and DEFINITY Use to Defend Growth
In FY2025, Lantheus Medical Imaging drove market penetration by deepening use of PYLARIFY and DEFINITY in existing accounts, not just adding sites. Lantheus Holdings, Inc. reported about $1.5 billion in FY2025 revenue, with PYLARIFY still the main growth engine, so share defense depends on referral flow, payer access, and reliable supply.
| FY2025 data | Value |
|---|---|
| Lantheus Holdings, Inc. revenue | About $1.5 billion |
| Main growth driver | PYLARIFY |
What is included in the product
Detailed Word Document
Editable Excel File
Market Development
From Academic Centers to Community Sites
Lantheus Holdings, Inc. grows the same approved tracer from a few academic centers into many community sites, outpatient imaging groups, community hospitals, and multi-specialty practices. This widens use without changing the molecule, so PYLARIFY can reach more patients at the point of care. It matters most in prostate cancer, where access to PSMA PET is still uneven across U.S. geographies.
Two-Step Adoption Outside Major Metros
Two-step adoption outside major metros starts in flagship sites, then moves to local workflow replication. Smaller and mid-sized markets usually lag because reimbursement and staffing slow uptake, so Lantheus Holdings, Inc. keeps building awareness with urologists, oncologists, and imaging physicians. The aim is normalized use beyond the top metros, where scale and repeat ordering can widen reach.
Partner-Led Geographic Expansion
Partner-led geographic expansion lets Lantheus Holdings, Inc. test 1 or 2 markets first, using local partners where approvals, reimbursement, and distribution already exist. That keeps fixed costs far below a direct launch, which matters when building outside the U.S. is often a multi-year, high-cash burn step.
For Lantheus Holdings, Inc., this is the most capital-efficient way to add geography because it extends approved imaging agents without funding a full sales force, medical team, and supply network upfront. It also lowers execution risk while preserving cash for late-stage development and core U.S. growth.
Three Clinical Workflows Expand Use
YLARIFY expands across three clear workflows: initial staging, recurrence assessment, and treatment planning. Each use case brings in more urology, oncology, and nuclear medicine users without changing the product, so adoption can grow inside the same approved label. That is classic market development: one agent, more clinical settings, and a wider addressable base for Lantheus Medical Imaging.
Health-System Rollouts Scale Across 10s of Sites
Large health systems can approve one imaging protocol at a flagship site, then roll it out across 10s of hospitals and outpatient centers. For Lantheus Holdings, Inc., that matters because integrated delivery networks can turn one clinical win into network-wide use, lifting demand without chasing a new customer base. This is a classic market development move: use a proven asset in one site, then expand it across the same health system.
- One pilot can unlock many sites.
- Standardized protocols speed adoption.
PYLARIFY Expands FY2025 Reach Across More Sites
In FY2025, Lantheus Medical Imaging kept pushing PYLARIFY from flagship centers into community sites and health-system networks, which is market development: same tracer, more places of use. A single protocol can still spread across 10+ hospitals and outpatient centers, so access widens without changing the label.
| FY2025 signal | Use |
|---|---|
| 1 pilot site | Triggers network rollout |
| 10+ sites | One protocol, broader reach |
Preview the Actual Deliverable
Lantheus Medical Imaging Reference Sources
This is the actual Lantheus Medical Imaging Amsoff Matrix analysis document you'll receive upon purchase – no surprises, just the same professional-quality file. The preview below is taken directly from the full report, so what you see here is what you get. Once purchased, you'll unlock the complete version immediately.
Product Development
Tau PET Through the Cerveau Asset
The Cerveau deal added 1 neuroimaging platform: MK-6240 tau PET. It is product development because Lantheus Medical Imaging is selling a new tracer family to its existing imaging base, not entering a new market from scratch. MK-6240 extends Lantheus Holdings, Inc. into Alzheimer's and other neurodegenerative uses, broadening the mix beyond oncology and cardiology.
Next-Generation PSMA Radiotracers
Next-generation PSMA radiotracers matter because better image quality, longer or better-tuned half-life, and easier manufacturing can improve scan reliability and site workflow. For Lantheus Holdings, Inc., follow-on radiotracers can defend the prostate cancer franchise by keeping hospitals and imaging centers inside its product set. In radiopharma, even small technical gains can shift site preference, and that is often how a first mover keeps share.
Therapeutic Radiopharmaceutical Pipeline
In 2025, Lantheus Holdings, Inc. is building a 2-model setup: diagnostics first, then radiotherapeutics. That matters because imaging and therapy monetize differently, so one prostate cancer patient can support 2 revenue streams instead of 1. With prostate-targeted assets like PNT2002, the path points to PSMA-based theranostic care, where scan, select, and treat happen in one flow.
Label and Workflow Enhancements
Label and workflow upgrades can add 2 to 3 more reimbursed use cases without changing the molecule, and in imaging, the evidence package can matter as much as chemistry. Lantheus Holdings, Inc. can widen adoption by backing clinical data, easier administration, and simpler handling, which are classic line-extension levers. This matters in a market where each new label can lift site throughput and payer access faster than a new tracer launch. For Lantheus Medical Imaging, that makes product development a low-capex way to extend the life and value of existing assets.
Pairing Diagnostics with Therapy
Pairing diagnostics with therapy links one clinical pathway from patient selection to treatment follow-up, so each launch can do more than a stand-alone asset. Lantheus Holdings, Inc. is well placed to connect imaging and treatment in the same disease area, which can deepen use across the full care path. That is where product development starts to compound: better targeting, better monitoring, and a tighter clinical story.
Lantheus Extends Imaging Base With New Tracers and PSMA Labels
In 2025, Lantheus Medical Imaging's product development path is about extending its imaging base with new tracers and labels, not entering a new market. MK-6240 and next-gen PSMA assets can add 2 to 3 reimbursed use cases, support 2 revenue streams in theranostics, and help defend prostate cancer share through better workflow and scan quality.
| 2025 item | Why it fits |
|---|---|
| MK-6240 | New tracer family |
| PSMA line extensions | More use cases |
Diversification
Therapeutics Add a Second Growth Engine
Therapeutics add a second growth engine beyond imaging, and that makes Lantheus Holdings, Inc. less dependent on a single diagnostic lane. Radiotherapeutics can support six-figure treatment pricing, more repeat use, and tighter clinical adoption than one-time imaging tests, which can lift mix and margin quality. This is the clearest diversification move for Lantheus Holdings, Inc., and it broadens the business from a seller of scans to a player in treatment.
Beyond Prostate Cancer into 2 Adjacent Areas
For Lantheus Medical Imaging, moving beyond prostate cancer can open two adjacent demand pools: neurology and broader oncology. A tau PET franchise and other neuro assets would cut concentration risk, especially when one product drives most earnings sensitivity. Diversification works best when it adds both disease breadth and new buying centers, not just more labels.
More Customer Segments, More Resilience
Lantheus Holdings, Inc. can move from one buying group to four, spanning radiology, cardiology, neurology, and oncology. Each segment buys on different cycles and responds to different clinical needs, so a setback in one area does not hit all demand at once. Over a 3- to 5-year horizon, that spread makes revenue less tied to a single workflow and more durable.
Acquisition Speeds Entry by 5 to 7 Years
Acquisition can cut entry time by 5 to 7 years versus relying on internal programs alone. In 2025, Lantheus Holdings, Inc. had about $1.53 billion in revenue, and the Cerveau deal showed it can buy platform assets with clinical value already built in, speeding commercialization and creating room for tuck-in deals.
Multi-Asset Platform Reduces Single-Product Risk
Lantheus Medical Imaging's long-term target is a multi-asset platform, not a one-product bet. By building imaging agents, therapy candidates, and companion diagnostics, Lantheus Holdings, Inc. can reduce dependence on any one reimbursement cycle or launch. That mix spreads risk across diseases, modalities, and cash-flow sources, which is the most durable form of diversification in this sector.
Lantheus' Diversification Push Could Reduce Reliance on One Product
Diversification for Lantheus Medical Imaging means adding therapies, new disease areas, and more buying centers so one product or one reimbursement cycle does not carry the whole business. In 2025, Lantheus Holdings, Inc. generated about $1.53 billion in revenue, so even small mix shifts can matter. The Cerveau deal also showed that buying platform assets can speed entry versus building alone.
| 2025 metric | Value |
|---|---|
| Revenue | $1.53 billion |
| Buying centers | 4 |
| Entry time saved by acquisition | 5 to 7 years |
Frequently Asked Questions
Lantheus Holdings, Inc. wins share by concentrating on 2 scaled franchises, PYLARIFY and DEFINITY, and then layering access, field education, and supply reliability on top. In practice, that means more scans per site, better payer conversion, and stronger retention inside existing accounts. The goal is to defend utilization across 3 major clinical areas: oncology, cardiology, and neurology.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.